Table 2 Effect of simvastatin allocation on vascular and non-vascular causes of death
Cause of death | Simvastatin-allocated (10,269) | Placebo- allocated (10,267) | Death rate ratio (& 95% CI) | P-value |
|---|---|---|---|---|
Coronary | Â | Â | Â | Â |
   Acute MI | 141 (1.4%) | 191 (1.9%) | 0.73 (0.59 – 0.91) |  |
   Sudden death | 147 (1.4%) | 154 (1.5%) | 0.95 (0.75 – 1.19) |  |
   Heart failure* | 65 (0.6%) | 78 (0.8%) | 0.82 (0.59 – 1.15) |  |
   Other coronary | 234 (2.3%) | 284 (2.8%) | 0.82 (0.69 – 0.97) |  |
   Subtotal: Coronary | 587 (5.7%) | 707 (6.9%) | 0.82 (0.74 – 0.92) | 0.0005 |
Stroke | Â | Â | Â | Â |
   Haemorrhagic | 23 (0.2%) | 24 (0.2%) | 0.95 (0.54 – 1.68) |  |
   Ischaemic (or unknown) | 73 (0.7%) | 95 (0.9%) | 0.76 (0.56 – 1.03) |  |
   Subtotal: Stroke | 96 (0.9%) | 119 (1.2%) | 0.80 (0.61 – 1.05) | 0.1 |
Other vascular | Â | Â | Â | Â |
   Peripheral vascular | 58 (0.6%) | 63 (0.6%) | 0.91 (0.64 – 1.30) |  |
   Other cardiac* | 40 (0.4%) | 48 (0.5%) | 0.83 (0.54 – 1.25) |  |
   Subtotal: Other vascular | 98 (1.0%) | 111 (1.1%) | 0.88 (0.67 – 1.15) | 0.3 |
VASCULAR | 781 (7.6%) | 937 (9.1%) | 0.83 (0.75 – 0.91) | <0.0001 |
Neoplastic | Â | Â | Â | Â |
   Respiratory | 127 (1.2%) | 133 (1.3%) | 0.94 (0.74 – 1.20) |  |
   Gastrointestinal | 112 (1.1%) | 103 (1.0%) | 1.08 (0.82 – 1.41) |  |
   Genitourinary | 47 (0.5%) | 46 (0.4%) | 1.01 (0.67 – 1.52) |  |
   All others | 73 (0.7%) | 62 (0.6%) | 1.17 (0.83 – 1.63) |  |
   Subtotal: Neoplastic | 359 (3.5%) | 345 (3.4%) | 1.03 (0.89 – 1.19) | 0.7 |
Other non-vascular | Â | Â | Â | Â |
   Respiratory | 90 (0.9%) | 114 (1.1%) | 0.78 (0.59 – 1.03) |  |
   Gastrointestinal | 35 (0.3%) | 41 (0.4%) | 0.85 (0.54 – 1.33) |  |
   Other medical†| 47 (0.5%) | 49 (0.5%) | 0.95 (0.64 – 1.42) |  |
   Non-medical | 16 (0.2%) | 21 (0.2%) | 0.75 (0.40 – 1.44) |  |
NON-VASCULAR | 547 (5.3%) | 570 (5.6%) | 0.95 (0.85 – 1.07) | 0.4 |
ALL DEATHS | 1328 (12.9%) | 1507 (14.7%) | 0.87 (0.81 – 0.94) | 0.0003 |